|
Session 113
Poster Abstracts
HIV Drug Resistance: Prediction of Emergence
Tuesday, 1 - 4 pm
Poster Hall |
| 637 |
Failure to Fit with the Second Phase Dynamics Is Associated with Virological Rebound and Viral Evolution in Heavily Pretreated Patients Receiving Resistance Testing-guided HAART
Valerio Tozzi*1, R Bellagamba1, J Ivanovic1, F Castiglione2, A Amendola1, C Gori1, M Capobianchi1, C Perno1, A Antinori1, P Narciso1, and Collaborative Group for the Clinical Use of Genotype Resistance Test
1Natl Inst of Infectious Diseases, L Spallanzani, Rome, Italy and 2Natl Res Council, Rome, Italy |
638
 |
Drug Resistance Outcomes at 48 Weeks in the OK04 Trial: A Comparative Trial of Single-drug Maintenance Therapy with Lopinavir/Ritonavir vs Triple Therapy with LPV/r
Jose Arribas*1, F Pulido2, R Delgado2, E Cabrero3, J Pasquau4, J Portilla5, P Miralles6, A Ocampo7, C Cepeda2, M Norton8, and OK04 Study Group
1Hosp La Paz, Madrid, Spain; 2Hosp 12 de Octubre, Madrid, Spain; 3Abbott Labs, Madrid, Spain; 4Hosp Virgen de las Nieves, Granada, Spain; 5Hosp Gen, Alicante, Spain; 6Hosp Gregorio Maranon, Spain; 7Hosp Xeral Cies, Vigo, Spain; and 8Abbott Labs, Chicago, IL, US |
| 639 |
Low-frequency Mutations Substantially Increase the Prevalence of Transmitted Drug Resistance and Greatly Strengthen the Relationship between Resistance Mutations and Virologic Failure
Jeffrey Johnson*1, J F Li1, X Wei1, J Lipscomb1, A Smith1, C Stone2, D Irlbeck3, M Monsour1, E Lanier3, and W Heneine1
1CDC, Atlanta, GA, US; 2GlaxoSmithKline, Stevenage, UK; and 3GlaxoSmithKline, Research Triangle Park, NC, US |
|
